Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 139
Titolo Tipologia Data di pubblicazione Autori File
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 01 - Articolo su rivista 2025 Malighetti, FedericaVilla, MatteoPelucchi, SaraAroldi, AndreaCortinovis, Diego LuigiCazzaniga, Marina ElenaMologni, LucaRamazzotti, DanieleCordani, Nicoletta +
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC) 01 - Articolo su rivista 2025 Clementi, Thoma DarioCazzaniga, Marina Elena +
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) 01 - Articolo su rivista 2025 Cazzaniga M. +
Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer 01 - Articolo su rivista 2025 Cazzaniga M. E. +
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial 01 - Articolo su rivista 2025 Cazzaniga, MECordani, NGalimberti, S +
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 01 - Articolo su rivista 2024 Foti G.Citerio G.Pesci A.Valsecchi M. G.Cazzaniga M.Bellani G.Bruno R.Biondi A.Bettini L. R.Beretta I. +
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 01 - Articolo su rivista 2024 Bonfanti P.Lombardi A.Invernizzi P.Gerussi A.Citerio G.Biondi A.Valsecchi M. G.Cazzaniga M. E.Foti G.Bettini L. R. +
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 01 - Articolo su rivista 2024 Cazzaniga M. E.Zambelli A. +
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions(Front. Oncol., (2023), 13, (1249160), 10.3389/fonc.2023.1249160) 99 - Altro 2024 Cazzaniga M. +
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 01 - Articolo su rivista 2023 Zambelli A.Cazzaniga M. E. +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
A multidisciplinary approach to screen the post-COVID-19 conditions 01 - Articolo su rivista 2023 Squillace N.Rossi E.Bellelli G.Pozzi M.Luppi F.Strepparava M. G.Ferrarese C.Bonfanti P.Bellani G.Biondi A.Cazzaniga M. E.Citerio G.Foti G.Valsecchi M. G.Beretta E. M.Spolti A.Ferlicca D.Bettini F.Bellin V.Meroni V.Gatti S.Bronco A.Ripa C.Sosio S.Faverio P.Monzani A.Ferrara M. C.Zarcone C.Beretta S.Salvarani V. +
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 01 - Articolo su rivista 2023 Bonfanti P.Cazzaniga M. E. +
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients 01 - Articolo su rivista 2023 Cazzaniga M. E. +
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 01 - Articolo su rivista 2023 Cazzaniga, Marina EBonfanti, Paolo +
Mostrati risultati da 1 a 20 di 139
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile